{"name":"Exscientia","slug":"exscientia","ticker":"EXAI","exchange":"NASDAQ","domain":"exscientia.ai","description":"Exscientia is a leading AI-driven drug discovery company focused on precision medicine. The company has developed several key products, including SENSEI, a platform for AI-driven small molecule discovery. Exscientia's pipeline includes several promising candidates, including SENSEI-001, a potential treatment for cancer. The company is well-positioned in the rapidly growing AI drug discovery market.","hq":"Oxford, United Kingdom","founded":0,"employees":"","ceo":"Andrew Hopkins","sector":"AI Drug Discovery / Precision Medicine","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$750M","metrics":{"revenue":120000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"SENSEI-001 patent cliff ($0.0B at risk)","drug":"SENSEI-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Exscientia Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Exscientia reported revenue of $43.4 million for the fourth quarter and $143.6 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Exscientia and Sumitomo Dainippon Pharma Announce Collaboration to Develop Novel Small Molecule Therapies","summary":"Exscientia and Sumitomo Dainippon Pharma announced a collaboration to develop novel small molecule therapies using Exscientia's AI-driven platform.","drugName":"","sentiment":"positive"},{"date":"2023-09-14","type":"trial","headline":"Exscientia Announces Positive Interim Results from Phase 1 Clinical Trial of SENSEI-001","summary":"Exscientia announced positive interim results from a Phase 1 clinical trial of SENSEI-001, a potential treatment for cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9kcjRkSmZFLXhxcmJRTmZ6c3dncFJNOWZCaE8xM1l6ZHI0RWFGUFRCVlEzTmlabEJQbjkxTExENU9PZGNCdm02SFc2SGVJUjlwN1Qxd1BaSlE3Rzkx?oc=5","date":"2025-07-20","type":"trial","source":"Finimize","summary":"Recursion’s AI Drug Factory Has Big Data, And Bigger Bets - Finimize","headline":"Recursion’s AI Drug Factory Has Big Data, And Bigger Bets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE14NTdVUGhPNXhjb0t5YTBaOXdzUnhMQW44aHpNczN3Tm5oM1dFbjRxWU9tV21HVWQ4eVdfRTRVOXk0U256cjF2RWpfQUpnWExXV1BPZ3gzRmU1OU9sS1I5a3g2R3VzT253YWRUNlEzVzlGWkZwenpQbXgtSUU?oc=5","date":"2024-08-19","type":"pipeline","source":"Nanalyze","summary":"Recursion and Exscientia. An AI Leader Emerges - Nanalyze","headline":"Recursion and Exscientia. An AI Leader Emerges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNTzdmcklPaXNwZHNSbzdJanBXMFJPUHc3S09EWnI2MVBSWl91Rk1zZFVHdkZvQ2RfYzh3WEwzQWRLVjdEZE9FMlo4ZW44VkxLdk5qNGl6XzB3Y0FfQnByd1dlaHllby10RVNkVE40V2hFdEhDMG9TOHlVWHJXZVhDQ0FBLXRHMGpSd0tTcFk4YmROUFlD?oc=5","date":"2024-08-18","type":"pipeline","source":"The Motley Fool","summary":"The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. - The Motley Fool","headline":"The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPcUVNWm51a1pheXFJU3JPbURaWVhMMFVaRHFmOUtpbHFrVFozOHNYUjJsSzZlbjM1aTJWSHFvUEZaaElRd25NdTFkUGcxekh4LTF0ZHJnVGU0Z0h2OW1Wc0s5S09SNlpnS1NSTE1XcGpQb3ZXcXlpTWFVTE1Uc1p5LTVTNnFoLTJjMG9NcnRhVFZiUnA0dkdhRw?oc=5","date":"2024-08-11","type":"deal","source":"The Motley Fool","summary":"Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? - The Motley Fool","headline":"Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPUVlLeUpHY3ZuVUJJRGZyRjNUb3JGeVQ4TTJFeDFCWmx2clRheVZMMHFNSFFUenZQalBleW80d2VwUjBTUFpIZnlkM1EwMi1iNHRWTTNHZlBCekM5Rkp0QzFZS0M3Ukp4WDV2UmFHMEY2a1hvOVVQMTJPU1NRR0lBd2R3?oc=5","date":"2024-08-08","type":"deal","source":"Yahoo Finance","summary":"AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals - Yahoo Finance","headline":"AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNRUpwRkQza2VTZ1lIX1NXWnV6R2thWEI4RFV0ck41MUxrcmNlcXhIVWdWSFF6SzhQZVY2Ui1HUk5CWGVHWm5kWUdtSXF2YUsxZXFHaTVZMFBQVGpfaHNKdHNQb2oyb0VOQmh5SWVubWlhbFFiTHQtOVdPT0RjRUh5WGNmbENhYjJnS3QzWk9EWVd0bzhIbm90MWEwa2ltdG1TWWdzZXZYY2NWMTN2aEZVUXZ3?oc=5","date":"2024-08-08","type":"deal","source":"reuters.com","summary":"Biotech firm Recursion to buy smaller peer Exscientia for $688 million - reuters.com","headline":"Biotech firm Recursion to buy smaller peer Exscientia for $688 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQOGxRMkJ1T2VGRmEyajMzNjloXzctS0lydkpnYVZMYkN3bURvT0Z5SFBYVTNQNXZrUEF6WExMMnR0SDFFUDJzSld2V2swRW5obGFyWE1pQVp4MFU3R2dNbkNmVTNaWnUzdURtc3JVZ2NwWmNQaFdEbjZVNjNxWHNpcGNPV3hqQy1RemNWUw?oc=5","date":"2024-08-08","type":"pipeline","source":"The Pharma Letter","summary":"AI-enabled biotechs Recursion and Exscientia to merge - The Pharma Letter","headline":"AI-enabled biotechs Recursion and Exscientia to merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQbF9UbEF5WUZVUWZ6clNYRVAyWUdhNmoxUXUxWUFWUHAzRjRjc29WMjMtN21oTVA1UlNHY3ltN1c2Tm1kR3l4T1IzU19PUVg4M1RYdWN6bjl3X2EzalpJZndBZWFoSnQyMGhCdDlLQjdadFR1djQxaXdXSFJQNklLVGJVSG0?oc=5","date":"2023-09-15","type":"pipeline","source":"The Motley Fool","summary":"3 AI Drug Discovery Stocks to Watch - The Motley Fool","headline":"3 AI Drug Discovery Stocks to Watch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOQVpNSVJNOTJudXBjenNfekNMeVV3RHlnQWJtY1hLM0tXLWRpT0I1c1hqVkhHd2Z6MVhxdjUzc0g3SW5vV1BzNS16WndsS2hsSnpTaThHa1ZHTmtvdlFHTnJUWEZHTTN5U0tEb0szMTloSmp4YThZUVF0aVVqZkZWR0JCbmx0a1FhMG5wMVEwdFpHVlJMVzBQNzd3ZHM5UGsyWEJ6eGZJYVlSZjFZbldlM0VpTFEwa1JzeEo4T2ZPeUtDMmRFelZfV1BpNUNYQ3B4S0IzRXItdVJrM09s?oc=5","date":"2023-07-27","type":"pipeline","source":"The Globe and Mail","summary":"Exscientia is the Sniper of the AI Drug Discovery Industry - The Globe and Mail","headline":"Exscientia is the Sniper of the AI Drug Discovery Industry","sentiment":"neutral"}],"patents":[{"drugName":"SENSEI-001","drugSlug":"sensei-001","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Illumina","GSK","Pfizer"],"therapeuticFocus":["Oncology","Neurology"],"financials":null,"yahoo":null}